.Pharmacolibrary.Drugs.ATC.L.L01DB07 .Pharmacolibrary.Drugs.ATC.L.L01DB07| name: | Mitoxantrone |
| ATC code: | L01DB07 | route: | intravenous |
| n-compartments | 3 |
Mitoxantrone is an antineoplastic agent in the class of anthracenediones, used for the treatment of certain types of cancer (including breast cancer, non-Hodgkin's lymphoma, and acute myeloid leukemia), and also for secondary progressive multiple sclerosis. It is an approved drug, although its use is limited by potential cardiac toxicity.
Pharmacokinetic parameters reported for adult cancer patients (various tumor types), predominantly female, with intravenous administration.
Launay, MC, et al., & Richard, B (1989). Population pharmacokinetics of mitoxantrone performed by a NONMEM method. Journal of pharmaceutical sciences 78(10) 877–880. DOI:10.1002/jps.2600781020 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2600798
Feldman, EJ, et al., & Plezia, P (1993). Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 11(10) 2002–2009. DOI:10.1200/JCO.1993.11.10.2002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8410125
Rago, RP, et al., & Dalton, WS (2003). Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer chemotherapy and pharmacology 51(4) 297–305. DOI:10.1007/s00280-003-0573-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12721757